Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines

Takeshi Fukami, Hiroshi Fukuhara, Masami Kuramochi, Tomoko Maruyama, Kana Isogai, Michiie Sakamoto, Shinichi Takamoto, Yoshinori Murakami

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

We previously identified TSLC1, a tumor suppressor gene in human nonsmall cell lung cancer (NSCLC). TSLC1 belongs to immunoglobulin superfamily molecules and is involved in cell adhesion. Loss of TSLC1 expression was strongly correlated with the promoter hypermethylation in several NSCLC cell lines. Here, we examined the methylation status of the TSLC1 gene promoter in 48 primary NSCLC tumors by bisulfite SSCP in combination with bisulfite sequencing. Six CpG sites around the promoter regions were significantly methylated in 21 of 48 primary NSCLC tumors (44%). Promoter methylation was more likely to be observed in relatively advanced tumors with TNM classification of pT2, pT3 or pT4 (19 of 33, 58%) than in those with pTI (2 of 15, 13%), suggesting that alteration of TSLC1 would be involved in the progression of human NSCLC. Loss of TSLC1 expression was also observed in 20 of 46 (43%) human cancer cell lines, including those from esophageal (3 of 3), gastric (8 of 9), ovarian (2 of 5), endometrial (2 of 2), breast (I of 3), colorectal (2 of 8) and small cell lung cancers (2 of 10). Combined analysis of promoter methylation and the allelic state in these cell lines indicated that the TSLC1 gene was often silenced not only by mono-allelic methylation associated with loss of the other allele but also through bi-allelic methylation. These results suggest that alteration of TSLC1 would be involved in advanced NSCLC as well as in many other human cancers.

Original languageEnglish
Pages (from-to)53-59
Number of pages7
JournalInternational Journal of Cancer
Volume107
Issue number1
DOIs
Publication statusPublished - 2003 Oct 20
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Methylation
Cell Line
Lung
Genes
Neoplasms
Single-Stranded Conformational Polymorphism
Neoplasm Staging
Small Cell Lung Carcinoma
Tumor Suppressor Genes
Genetic Promoter Regions
Cell Adhesion
Immunoglobulins
Stomach
Breast
Alleles
hydrogen sulfite

Keywords

  • Bi-allelic methylation
  • Nonsmall cell lung cancer
  • Promoter methylation
  • TSLC1
  • Tumor suppressor gene

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines. / Fukami, Takeshi; Fukuhara, Hiroshi; Kuramochi, Masami; Maruyama, Tomoko; Isogai, Kana; Sakamoto, Michiie; Takamoto, Shinichi; Murakami, Yoshinori.

In: International Journal of Cancer, Vol. 107, No. 1, 20.10.2003, p. 53-59.

Research output: Contribution to journalArticle

Fukami, T, Fukuhara, H, Kuramochi, M, Maruyama, T, Isogai, K, Sakamoto, M, Takamoto, S & Murakami, Y 2003, 'Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines', International Journal of Cancer, vol. 107, no. 1, pp. 53-59. https://doi.org/10.1002/ijc.11348
Fukami, Takeshi ; Fukuhara, Hiroshi ; Kuramochi, Masami ; Maruyama, Tomoko ; Isogai, Kana ; Sakamoto, Michiie ; Takamoto, Shinichi ; Murakami, Yoshinori. / Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines. In: International Journal of Cancer. 2003 ; Vol. 107, No. 1. pp. 53-59.
@article{87fffedbe36649cd8d2d03074e0f5c13,
title = "Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines",
abstract = "We previously identified TSLC1, a tumor suppressor gene in human nonsmall cell lung cancer (NSCLC). TSLC1 belongs to immunoglobulin superfamily molecules and is involved in cell adhesion. Loss of TSLC1 expression was strongly correlated with the promoter hypermethylation in several NSCLC cell lines. Here, we examined the methylation status of the TSLC1 gene promoter in 48 primary NSCLC tumors by bisulfite SSCP in combination with bisulfite sequencing. Six CpG sites around the promoter regions were significantly methylated in 21 of 48 primary NSCLC tumors (44{\%}). Promoter methylation was more likely to be observed in relatively advanced tumors with TNM classification of pT2, pT3 or pT4 (19 of 33, 58{\%}) than in those with pTI (2 of 15, 13{\%}), suggesting that alteration of TSLC1 would be involved in the progression of human NSCLC. Loss of TSLC1 expression was also observed in 20 of 46 (43{\%}) human cancer cell lines, including those from esophageal (3 of 3), gastric (8 of 9), ovarian (2 of 5), endometrial (2 of 2), breast (I of 3), colorectal (2 of 8) and small cell lung cancers (2 of 10). Combined analysis of promoter methylation and the allelic state in these cell lines indicated that the TSLC1 gene was often silenced not only by mono-allelic methylation associated with loss of the other allele but also through bi-allelic methylation. These results suggest that alteration of TSLC1 would be involved in advanced NSCLC as well as in many other human cancers.",
keywords = "Bi-allelic methylation, Nonsmall cell lung cancer, Promoter methylation, TSLC1, Tumor suppressor gene",
author = "Takeshi Fukami and Hiroshi Fukuhara and Masami Kuramochi and Tomoko Maruyama and Kana Isogai and Michiie Sakamoto and Shinichi Takamoto and Yoshinori Murakami",
year = "2003",
month = "10",
day = "20",
doi = "10.1002/ijc.11348",
language = "English",
volume = "107",
pages = "53--59",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines

AU - Fukami, Takeshi

AU - Fukuhara, Hiroshi

AU - Kuramochi, Masami

AU - Maruyama, Tomoko

AU - Isogai, Kana

AU - Sakamoto, Michiie

AU - Takamoto, Shinichi

AU - Murakami, Yoshinori

PY - 2003/10/20

Y1 - 2003/10/20

N2 - We previously identified TSLC1, a tumor suppressor gene in human nonsmall cell lung cancer (NSCLC). TSLC1 belongs to immunoglobulin superfamily molecules and is involved in cell adhesion. Loss of TSLC1 expression was strongly correlated with the promoter hypermethylation in several NSCLC cell lines. Here, we examined the methylation status of the TSLC1 gene promoter in 48 primary NSCLC tumors by bisulfite SSCP in combination with bisulfite sequencing. Six CpG sites around the promoter regions were significantly methylated in 21 of 48 primary NSCLC tumors (44%). Promoter methylation was more likely to be observed in relatively advanced tumors with TNM classification of pT2, pT3 or pT4 (19 of 33, 58%) than in those with pTI (2 of 15, 13%), suggesting that alteration of TSLC1 would be involved in the progression of human NSCLC. Loss of TSLC1 expression was also observed in 20 of 46 (43%) human cancer cell lines, including those from esophageal (3 of 3), gastric (8 of 9), ovarian (2 of 5), endometrial (2 of 2), breast (I of 3), colorectal (2 of 8) and small cell lung cancers (2 of 10). Combined analysis of promoter methylation and the allelic state in these cell lines indicated that the TSLC1 gene was often silenced not only by mono-allelic methylation associated with loss of the other allele but also through bi-allelic methylation. These results suggest that alteration of TSLC1 would be involved in advanced NSCLC as well as in many other human cancers.

AB - We previously identified TSLC1, a tumor suppressor gene in human nonsmall cell lung cancer (NSCLC). TSLC1 belongs to immunoglobulin superfamily molecules and is involved in cell adhesion. Loss of TSLC1 expression was strongly correlated with the promoter hypermethylation in several NSCLC cell lines. Here, we examined the methylation status of the TSLC1 gene promoter in 48 primary NSCLC tumors by bisulfite SSCP in combination with bisulfite sequencing. Six CpG sites around the promoter regions were significantly methylated in 21 of 48 primary NSCLC tumors (44%). Promoter methylation was more likely to be observed in relatively advanced tumors with TNM classification of pT2, pT3 or pT4 (19 of 33, 58%) than in those with pTI (2 of 15, 13%), suggesting that alteration of TSLC1 would be involved in the progression of human NSCLC. Loss of TSLC1 expression was also observed in 20 of 46 (43%) human cancer cell lines, including those from esophageal (3 of 3), gastric (8 of 9), ovarian (2 of 5), endometrial (2 of 2), breast (I of 3), colorectal (2 of 8) and small cell lung cancers (2 of 10). Combined analysis of promoter methylation and the allelic state in these cell lines indicated that the TSLC1 gene was often silenced not only by mono-allelic methylation associated with loss of the other allele but also through bi-allelic methylation. These results suggest that alteration of TSLC1 would be involved in advanced NSCLC as well as in many other human cancers.

KW - Bi-allelic methylation

KW - Nonsmall cell lung cancer

KW - Promoter methylation

KW - TSLC1

KW - Tumor suppressor gene

UR - http://www.scopus.com/inward/record.url?scp=0042916159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042916159&partnerID=8YFLogxK

U2 - 10.1002/ijc.11348

DO - 10.1002/ijc.11348

M3 - Article

C2 - 12925956

AN - SCOPUS:0042916159

VL - 107

SP - 53

EP - 59

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -